These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 48324)

  • 1. An approach to experimental scleroderma, using urinary glycosaminoglycans from patients with systemic scleroderma.
    Ishikawa H; Suzuki S; Horiuchi R; Sato H
    Acta Derm Venereol; 1975; 55(2):97-107. PubMed ID: 48324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization of scleroderma-inducing glycosaminoglycan.
    Ishikawa H; Kitabatake M; Akiyama F
    Acta Derm Venereol; 1988; 68(5):378-84. PubMed ID: 2461019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scleroderma-inducing glycosaminoglycan in the urine of patients with systemic scleroderma.
    Ishikawa H; Saito Y; Yamakage A; Kitabatake M
    Dermatologica; 1978; 156(4):193-204. PubMed ID: 564296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urinary glycosaminoglycans in systemic scleroderma].
    Astakhova TA; Balabanova RM
    Ter Arkh; 1980; 52(12):100-5. PubMed ID: 7245055
    [No Abstract]   [Full Text] [Related]  

  • 5. [Urinary excretion of mucopolysaccharides in patients with collagen diseases (author's transl)].
    Kreysel HW; Köhler A
    Dermatologica; 1974; 148(1):19-27. PubMed ID: 4275497
    [No Abstract]   [Full Text] [Related]  

  • 6. Lymphocyte responsiveness to urinary glycosaminoglycan in systemic scleroderma.
    Ishikawa H; Hattori A
    Dermatologica; 1979; 158(5):328-33. PubMed ID: 312217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ultrastructure of the skin in systemic scleroderma].
    Iakovleva GI; Mul'diiarov PIa; Guseva NG; Pavlov GG
    Arkh Patol; 1975; 37(3):32-7. PubMed ID: 1093525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Behavior of urinary acid mucopolysaccharides in dermatological collagen diseases].
    Rossi A
    G Ital Dermatol Minerva Dermatol; 1969 Dec; 44(12):641-5. PubMed ID: 4243640
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure to demonstrate fibrotic changes in the skin of mice injected with glycosaminoglycan fractions from the urine of scleroderma patients.
    Fox PK; White DD; Cavanagh M; Davies MG; Wusterman F
    Dermatologica; 1982 Feb; 164(2):90-4. PubMed ID: 7075853
    [No Abstract]   [Full Text] [Related]  

  • 10. Significant increase of urinary low-sulfated heparan-sulfate-related protein in patients with severe systemic scleroderma.
    Kitabatake M; Ishikawa H; Uchiyama Y
    Dermatologica; 1987; 174(4):166-72. PubMed ID: 3108042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glycosaminoglucuronates and their fractions in the urine of patients with scleroderma].
    Kowalczyk J; Oszewska Z
    Przegl Dermatol; 1978; 65(5):527-33. PubMed ID: 725096
    [No Abstract]   [Full Text] [Related]  

  • 12. Connective tissue in scleroderma. A biochemical study on the correlation of fractionated glycosaminoglycans and collagen in human skin.
    Uitto J; Helin G; Helin P; Lorenzen I
    Acta Derm Venereol; 1971; 51(6):401-6. PubMed ID: 4109419
    [No Abstract]   [Full Text] [Related]  

  • 13. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.
    Yamamoto T; Nishioka K
    Clin Immunol; 2002 Jan; 102(1):77-83. PubMed ID: 11781070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts.
    Murota H; Hamasaki Y; Nakashima T; Yamamoto K; Katayama I; Matsuyama T
    Arthritis Rheum; 2003 Apr; 48(4):1117-25. PubMed ID: 12687556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Connective tissue metabolism including cytokines in scleroderma.
    Smith EA
    Curr Opin Rheumatol; 1992 Dec; 4(6):869-77. PubMed ID: 1457283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New developments in the pathology, pathophysiology and therapy of systemic scleroderma].
    Asboe-Hansen G
    Hautarzt; 1980 Nov; 31(11):584-7. PubMed ID: 7451139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma.
    Ozgen M; Koca SS; Isik A; Ozercan IH
    J Rheumatol; 2010 Mar; 37(3):678-9. PubMed ID: 20197571
    [No Abstract]   [Full Text] [Related]  

  • 18. The characterization of normal and scleroderma skin fibroblasts cultured in a collagen gel matrix.
    Mayes MD; Walker ER; Frederickson RG; Prince RK; DiBartolomeo AG
    J Rheumatol; 1988 Feb; 15(2):268-75. PubMed ID: 3283357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of sclerosis-inducing glycosaminoglycan in the skin of an amine-induced experimental skin sclerosis.
    Ishikawa H; Yamakage A; Kitabatake M; Katayama H; Saito Y
    Dermatologica; 1980; 161(3):145-51. PubMed ID: 7398992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation of urinary acid glycosaminoglycan and collagen metabolite excretion with disease activity in generalized scleroderma.
    Blumenkrantz N; Asboe-Hansen G
    Acta Derm Venereol; 1980; 60(1):39-43. PubMed ID: 6153832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.